Parecoxib

製品コードS4656 バッチS465601

印刷

化学情報

Synonyms

SC-69124, Valus-P, Vorth-P

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₁₉H₁₈N₂O₄S

分子量

370.42

CAS No.

198470-84-7

Solubility (25°C)*

体外

DMSO

74 mg/mL (199.77 mM)

Ethanol

2 mg/mL (5.39 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Parecoxib（SC-69124、Valus-P、Vorth-P）は、選択的COX2阻害剤です。
in vivo	Parecoxib, a selected cyclooxygenase-2 inhibitor, ameliorates neurologic deficits in the behavior studies and brain damage, including neuronal death, and brain edema in the MCP-1 and NeuN immunostaining in rats subjected to SAH(Subarachnoid Hemorrhage). This compound is able to reduce early COX2 expression via inhibiting cJNK (p55) expression (dose-dependently), reduce IL-1β, IL-6 and MCP-1( at 2000 ug/kg/day at the time point of 24hr and 72hr after the induction of SAH), IL-8 (of the dosage of 2000 ug/kg/day at 24hr after the induction of SAH), and also reduce cleaved caspase-1 (at 1000 and 2000 ug/kg/day) and Caspase-9a (at 2000 ug/kg/day). It reduces the NMDAR-1, and NMDAR-2a (at 1000 and 2000 ug/kg) after the induction of SAH.

製品説明

Parecoxib（SC-69124、Valus-P、Vorth-P）は、選択的COX2阻害剤です。

in vivo

Parecoxib, a selected cyclooxygenase-2 inhibitor, ameliorates neurologic deficits in the behavior studies and brain damage, including neuronal death, and brain edema in the MCP-1 and NeuN immunostaining in rats subjected to SAH(Subarachnoid Hemorrhage). This compound is able to reduce early COX2 expression via inhibiting cJNK (p55) expression (dose-dependently), reduce IL-1β, IL-6 and MCP-1( at 2000 ug/kg/day at the time point of 24hr and 72hr after the induction of SAH), IL-8 (of the dosage of 2000 ug/kg/day at 24hr after the induction of SAH), and also reduce cleaved caspase-1 (at 1000 and 2000 ug/kg/day) and Caspase-9a (at 2000 ug/kg/day). It reduces the NMDAR-1, and NMDAR-2a (at 1000 and 2000 ug/kg) after the induction of SAH.

プロトコル(参考用のみ)

動物実験	動物モデル	Female Sprague-Dawley rats
	投薬量	0.3, 1.5, 6.4 mg/kg
	投与方法	i.m.

参考

https://pubmed.ncbi.nlm.nih.gov/16810556/
http://www.omicsonline.org/open-access/parecoxib-a-selective-cyclooxygenase-inhibitor-attenuates-cjun-nterminalkinase-activation-in-experimental-subarachnoid-hemorrhage-induced-earlybrain-injury-2155-9562-1000294.php?aid=55129

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Electroacupuncture and Parecoxib Reduce Inflammatory Injury in a Primary Dysmenorrhea Rat Model: Investigating the Role of the COX-2/NF-κB/NLRP3 Pathway [ Journal of Pain Research, 2025, 3573-3592]	PubMed: nan
Electroacupuncture and Parecoxib Reduce Inflammatory Injury in a Primary Dysmenorrhea Rat Model: Investigating the Role of the COX-2/NF-κB/NLRP3 Pathway [ J Pain Res, 2025, 18:3573-3592]	PubMed: 40687333
Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. [ Theranostics, 2020, 10(8):3366-3381]	PubMed: 32206096
Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy [ Theranostics, 2020, 3366-3381]	PubMed: 32206096.0

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。